Genetic Analysis Using a Gene Panel in 87 Caucasian Patients With Colorectal Cancer: Own Results and Review of Literature.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 28 10 2018
revised: 12 12 2018
accepted: 20 12 2018
entrez: 4 2 2019
pubmed: 4 2 2019
medline: 21 3 2019
Statut: ppublish

Résumé

Colorectal cancer (CRC) is the third most common cancer worldwide. The prognosis between left- and right-sided CRC differs, partly due to baseline differences as vascular supply. The purpose of the present study was to investigate whether there are genetic differences between left- and right-sided CRC. Eighty-seven patients with CRC (mean age: 61 years) were retrospectively included in the study. Blood samples were used for genetic analysis, by applying the sequencing research panel Ion AmpliSeq Colon and Lung Cancer Research Panel V2. Statistical analyses included Chi-square tests, Kaplan-Meier survival curves, and univariate/multivariate Cox-regression analyses. By testing the sequence of 22 genes included in the panel, a significant difference was detected between left- and right-sided CRC regarding the expression of BRAF and DDR2 genes, with mutations occurring more often in the right-sided CRC. In the multivariate setting, left-sided CRC only turned out as a significant positive prognostic parameter regarding progression-free survival, irrespective of the type of chemotherapy or BRAF and NRAS mutations. Tumour location was the only parameter proven to be an independent prognostic factor for CRC in the present study.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Colorectal cancer (CRC) is the third most common cancer worldwide. The prognosis between left- and right-sided CRC differs, partly due to baseline differences as vascular supply. The purpose of the present study was to investigate whether there are genetic differences between left- and right-sided CRC.
PATIENTS AND METHODS METHODS
Eighty-seven patients with CRC (mean age: 61 years) were retrospectively included in the study. Blood samples were used for genetic analysis, by applying the sequencing research panel Ion AmpliSeq Colon and Lung Cancer Research Panel V2. Statistical analyses included Chi-square tests, Kaplan-Meier survival curves, and univariate/multivariate Cox-regression analyses.
RESULTS RESULTS
By testing the sequence of 22 genes included in the panel, a significant difference was detected between left- and right-sided CRC regarding the expression of BRAF and DDR2 genes, with mutations occurring more often in the right-sided CRC. In the multivariate setting, left-sided CRC only turned out as a significant positive prognostic parameter regarding progression-free survival, irrespective of the type of chemotherapy or BRAF and NRAS mutations.
CONCLUSION CONCLUSIONS
Tumour location was the only parameter proven to be an independent prognostic factor for CRC in the present study.

Identifiants

pubmed: 30711966
pii: 39/2/847
doi: 10.21873/anticanres.13184
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

847-852

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Maria A Smolle (MA)

Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria maria.smolle@medunigraz.at.
Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria.

Karl Kashofer (K)

Diagnostic and Research Institute for Pathology, Medical University of Graz, Graz, Austria.

Jakob M Riedl (JM)

Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria.

Michael Stotz (M)

Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria.

Armin Gerger (A)

Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH